Literature DB >> 32332015

The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures.

Lingling Chen1, Teniola Oke1, Nicholas Siegel2, Gady Cojocaru3, Ada J Tam1, Richard L Blosser1, Jessica Swailes1, John A Ligon1, Andriana Lebid4, Carol Morris5, Adam Levin5, Daniel S Rhee6, Fabian M Johnston7, Jonathan B Greer7, Christian F Meyer8, Brian H Ladle1, Elizabeth D Thompson9, Elizabeth A Montgomery10, Woonyoung Choi11, David J McConkey12, Robert A Anders9, Drew M Pardoll4, Nicolas J Llosa13.   

Abstract

PURPOSE: Clinical trials with immune checkpoint inhibition in sarcomas have demonstrated minimal response. Here, we interrogated the tumor microenvironment (TME) of two contrasting soft-tissue sarcomas (STS), rhabdomyosarcomas and undifferentiated pleomorphic sarcomas (UPS), with differing genetic underpinnings and responses to immune checkpoint inhibition to understand the mechanisms that lead to response. EXPERIMENTAL
DESIGN: Utilizing fresh and formalin-fixed, paraffin-embedded tissue from patients diagnosed with UPS and rhabdomyosarcomas, we dissected the TME by using IHC, flow cytometry, and comparative transcriptomic studies.
RESULTS: Our results demonstrated both STS subtypes to be dominated by tumor-associated macrophages and infiltrated with immune cells that localized near the tumor vasculature. Both subtypes had similar T-cell densities, however, their in situ distribution diverged. UPS specimens demonstrated diffuse intratumoral infiltration of T cells, while rhabdomyosarcomas samples revealed intratumoral T cells that clustered with B cells near perivascular beds, forming tertiary lymphoid structures (TLS). T cells in UPS specimens were comprised of abundant CD8+ T cells exhibiting high PD-1 expression, which might represent the tumor reactive repertoire. In rhabdomyosarcomas, T cells were limited to TLS, but expressed immune checkpoints and immunomodulatory molecules which, if appropriately targeted, could help unleash T cells into the rest of the tumor tissue.
CONCLUSIONS: Our work in STS revealed an immunosuppressive TME dominated by myeloid cells, which may be overcome with activation of T cells that traffic into the tumor. In rhabdomyosarcomas, targeting T cells found within TLS may be key to achieve antitumor response. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32332015      PMCID: PMC8772618          DOI: 10.1158/1078-0432.CCR-19-3416

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  58 in total

Review 1.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

2.  Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.

Authors:  Sandra P D'Angelo; Alexander N Shoushtari; Narasimhan P Agaram; Deborah Kuk; Li-Xuan Qin; Richard D Carvajal; Mark A Dickson; Mrinal Gounder; Mary Louise Keohan; Gary K Schwartz; William D Tap
Journal:  Hum Pathol       Date:  2014-11-15       Impact factor: 3.466

3.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Authors:  Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan
Journal:  Cancer Discov       Date:  2014-01-23       Impact factor: 39.397

4.  Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999.

Authors:  Amy M Linabery; Julie A Ross
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

5.  Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma.

Authors:  Manabu Shigeoka; Naoki Urakawa; Tetsu Nakamura; Mari Nishio; Taketo Watajima; Daisuke Kuroda; Takahide Komori; Yoshihiro Kakeji; Shuho Semba; Hiroshi Yokozaki
Journal:  Cancer Sci       Date:  2013-06-04       Impact factor: 6.716

6.  An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.

Authors:  Caroline S Jansen; Nataliya Prokhnevska; Viraj A Master; Martin G Sanda; Jennifer W Carlisle; Mehmet Asim Bilen; Maria Cardenas; Scott Wilkinson; Ross Lake; Adam G Sowalsky; Rajesh M Valanparambil; William H Hudson; Donald McGuire; Kevin Melnick; Amir I Khan; Kyu Kim; Yun Min Chang; Alice Kim; Christopher P Filson; Mehrdad Alemozaffar; Adeboye O Osunkoya; Patrick Mullane; Carla Ellis; Rama Akondy; Se Jin Im; Alice O Kamphorst; Adriana Reyes; Yuan Liu; Haydn Kissick
Journal:  Nature       Date:  2019-12-11       Impact factor: 49.962

Review 7.  Tertiary lymphoid structures in the era of cancer immunotherapy.

Authors:  Catherine Sautès-Fridman; Florent Petitprez; Julien Calderaro; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

8.  The Immune Landscape of Cancer.

Authors:  Vésteinn Thorsson; David L Gibbs; Scott D Brown; Denise Wolf; Dante S Bortone; Tai-Hsien Ou Yang; Eduard Porta-Pardo; Galen F Gao; Christopher L Plaisier; James A Eddy; Elad Ziv; Aedin C Culhane; Evan O Paull; I K Ashok Sivakumar; Andrew J Gentles; Raunaq Malhotra; Farshad Farshidfar; Antonio Colaprico; Joel S Parker; Lisle E Mose; Nam Sy Vo; Jianfang Liu; Yuexin Liu; Janet Rader; Varsha Dhankani; Sheila M Reynolds; Reanne Bowlby; Andrea Califano; Andrew D Cherniack; Dimitris Anastassiou; Davide Bedognetti; Younes Mokrab; Aaron M Newman; Arvind Rao; Ken Chen; Alexander Krasnitz; Hai Hu; Tathiane M Malta; Houtan Noushmehr; Chandra Sekhar Pedamallu; Susan Bullman; Akinyemi I Ojesina; Andrew Lamb; Wanding Zhou; Hui Shen; Toni K Choueiri; John N Weinstein; Justin Guinney; Joel Saltz; Robert A Holt; Charles S Rabkin; Alexander J Lazar; Jonathan S Serody; Elizabeth G Demicco; Mary L Disis; Benjamin G Vincent; Ilya Shmulevich
Journal:  Immunity       Date:  2018-04-05       Impact factor: 43.474

9.  Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer.

Authors:  Mary A Forget; Jeffrey L Voorhees; Sara L Cole; Duaa Dakhlallah; Ivory L Patterson; Amy C Gross; Leni Moldovan; Xiaokui Mo; Randall Evans; Clay B Marsh; Tim D Eubank
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

10.  Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.

Authors:  Anke E M van Erp; Yvonne M H Versleijen-Jonkers; Melissa H S Hillebrandt-Roeffen; Laurens van Houdt; Mark A J Gorris; Laura S van Dam; Thomas Mentzel; Marije E Weidema; C Dilara Savci-Heijink; Ingrid M E Desar; Hans H M Merks; Max M van Noesel; Janet Shipley; Winette T A van der Graaf; Uta E Flucke; Friederike A G Meyer-Wentrup
Journal:  Oncotarget       Date:  2017-07-07
View more
  15 in total

1.  FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma.

Authors:  Peter M Sullivan; Rajesh Kumar; Wei Li; Virginia Hoglund; Lingyan Wang; Yue Zhang; Megan Shi; Dusan Beak; Adam Cheuk; Michael C Jensen; Javed Khan; Dimiter S Dimitrov; Rimas J Orentas
Journal:  Mol Cancer Ther       Date:  2022-10-07       Impact factor: 6.009

Review 2.  Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies.

Authors:  Jacquelot N; Tellier J; Nutt Sl; Belz Gt
Journal:  Oncoimmunology       Date:  2021-03-29       Impact factor: 8.110

Review 3.  Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment.

Authors:  Jane Koo; Masanori Hayashi; Michael R Verneris; Alisa B Lee-Sherick
Journal:  Front Oncol       Date:  2020-12-14       Impact factor: 6.244

Review 4.  Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.

Authors:  Matthieu Roulleaux Dugage; Elise F Nassif; Antoine Italiano; Rastislav Bahleda
Journal:  Front Immunol       Date:  2021-12-03       Impact factor: 7.561

Review 5.  High-Grade Endometrial Stromal Sarcoma: Molecular Alterations and Potential Immunotherapeutic Strategies.

Authors:  Youngah Kim; Dohyang Kim; Woo Jung Sung; Jaewoo Hong
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

Review 6.  Emerging mechanisms of immunotherapy resistance in sarcomas.

Authors:  Vaia Florou; Breelyn A Wilky
Journal:  Cancer Drug Resist       Date:  2022-03-05

Review 7.  Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response.

Authors:  Tong Fu; Lei-Jie Dai; Song-Yang Wu; Yi Xiao; Ding Ma; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  J Hematol Oncol       Date:  2021-06-25       Impact factor: 17.388

8.  Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.

Authors:  Amy J Wisdom; Yvonne M Mowery; Cierra S Hong; Jonathon E Himes; Barzin Y Nabet; Xiaodi Qin; Dadong Zhang; Lan Chen; Hélène Fradin; Rutulkumar Patel; Alex M Bassil; Eric S Muise; Daniel A King; Eric S Xu; David J Carpenter; Collin L Kent; Kimberly S Smythe; Nerissa T Williams; Lixia Luo; Yan Ma; Ash A Alizadeh; Kouros Owzar; Maximilian Diehn; Todd Bradley; David G Kirsch
Journal:  Nat Commun       Date:  2020-12-17       Impact factor: 17.694

9.  Immunomodulating Profile of Dental Mesenchymal Stromal Cells: A Comprehensive Overview.

Authors:  Alessia Paganelli; Oriana Trubiani; Francesca Diomede; Alessandra Pisciotta; Roberto Paganelli
Journal:  Front Oral Health       Date:  2021-03-31

Review 10.  Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions.

Authors:  John A Ligon; Kristin M Wessel; Nirali N Shah; John Glod
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.